• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

利用加速度计作为预测阿片类戒断症状加重的指标。

Leveraging Accelerometry as a Prognostic Indicator for Increase in Opioid Withdrawal Symptoms.

机构信息

The Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology, Atlanta, GA 30332, USA.

School of Electrical and Computer Engineering, Georgia Institute of Technology, Atlanta, GA 30332, USA.

出版信息

Biosensors (Basel). 2022 Oct 26;12(11):924. doi: 10.3390/bios12110924.

DOI:10.3390/bios12110924
PMID:36354433
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9688173/
Abstract

Treating opioid use disorder (OUD) is a significant healthcare challenge in the United States. Remaining abstinent from opioids is challenging for individuals with OUD due to withdrawal symptoms that include restlessness. However, to our knowledge, studies of acute withdrawal have not quantified restlessness using involuntary movements. We hypothesized that wearable accelerometry placed mid-sternum could be used to detect withdrawal-related restlessness in patients with OUD. To study this, 23 patients with OUD undergoing active withdrawal participated in a protocol involving wearable accelerometry, opioid cues to elicit craving, and non-invasive Vagal Nerve Stimulation (nVNS) to dampen withdrawal symptoms. Using accelerometry signals, we analyzed how movements correlated with changes in acute withdrawal severity, measured by the Clinical Opioid Withdrawal Scale (COWS). Our results revealed that patients demonstrating sinusoidal-i.e., predominantly single-frequency oscillation patterns in their motion almost exclusively demonstrated an increase in the COWS, and a strong relationship between the maximum power spectral density and increased withdrawal over time, measured by the COWS (R = 0.92, = 0.029). Accelerometry may be used in an ambulatory setting to indicate the increased intensity of a patient's withdrawal symptoms, providing an objective, readily-measurable marker that may be captured ubiquitously.

摘要

治疗阿片类药物使用障碍(OUD)是美国面临的重大医疗挑战。由于戒断症状包括不安,因此患有 OUD 的个体很难保持戒断状态。然而,据我们所知,对急性戒断的研究尚未使用非自愿运动来量化不安。我们假设放置在胸骨中部的可穿戴加速度计可用于检测患有 OUD 的患者与戒断相关的不安。为了研究这一点,23 名正在经历主动戒断的 OUD 患者参与了一项涉及可穿戴加速度计、阿片类药物线索诱发渴求以及非侵入性迷走神经刺激(nVNS)以减轻戒断症状的方案。使用加速度计信号,我们分析了运动与急性戒断严重程度变化的相关性,急性戒断严重程度通过临床阿片类戒断量表(COWS)进行测量。我们的结果表明,在运动中表现出正弦波的患者,即主要表现为单一频率的振动模式的患者,几乎无一例外地表现出 COWS 的增加,以及最大功率谱密度与 COWS 测量的戒断时间之间的强烈关系(R = 0.92, = 0.029)。加速度计可能会在非卧床环境中用于指示患者戒断症状的强度增加,提供一种客观、易于测量的标志物,可以广泛捕获。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b1d0/9688173/c9c71d9423c7/biosensors-12-00924-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b1d0/9688173/57d3ea26940a/biosensors-12-00924-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b1d0/9688173/9f53c6079ddd/biosensors-12-00924-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b1d0/9688173/2b981bc49dd1/biosensors-12-00924-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b1d0/9688173/c9c71d9423c7/biosensors-12-00924-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b1d0/9688173/57d3ea26940a/biosensors-12-00924-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b1d0/9688173/9f53c6079ddd/biosensors-12-00924-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b1d0/9688173/2b981bc49dd1/biosensors-12-00924-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b1d0/9688173/c9c71d9423c7/biosensors-12-00924-g004.jpg

相似文献

1
Leveraging Accelerometry as a Prognostic Indicator for Increase in Opioid Withdrawal Symptoms.利用加速度计作为预测阿片类戒断症状加重的指标。
Biosensors (Basel). 2022 Oct 26;12(11):924. doi: 10.3390/bios12110924.
2
Extended-Release 7-Day Injectable Buprenorphine for Patients With Minimal to Mild Opioid Withdrawal.经改良的 7 天缓释注射用丁丙诺啡治疗轻至中度阿片类药物戒断症状。
JAMA Netw Open. 2024 Jul 1;7(7):e2420702. doi: 10.1001/jamanetworkopen.2024.20702.
3
Changes in Withdrawal and Craving Scores in Participants Undergoing Opioid Detoxification Utilizing Ibogaine.接受伊博加因进行阿片类药物脱毒治疗的参与者在戒断和渴求评分上的变化。
J Psychoactive Drugs. 2018 Jul-Aug;50(3):256-265. doi: 10.1080/02791072.2018.1447175. Epub 2018 Apr 2.
4
Management of opioid withdrawal and initiation of medications for opioid use disorder in the hospital setting.医院环境中阿片类药物戒断的管理和阿片类药物使用障碍药物的启用。
Hosp Pract (1995). 2022 Oct;50(4):251-258. doi: 10.1080/21548331.2022.2102776. Epub 2022 Jul 22.
5
Transcutaneous cervical vagus nerve stimulation reduces behavioral and physiological manifestations of withdrawal in patients with opioid use disorder: A double-blind, randomized, sham-controlled pilot study.经皮颈部迷走神经刺激可减轻阿片类药物使用障碍患者戒断的行为和生理表现:一项双盲、随机、假刺激对照的初步研究。
Brain Stimul. 2022 Sep-Oct;15(5):1206-1214. doi: 10.1016/j.brs.2022.08.017. Epub 2022 Aug 27.
6
The Perceived Role of Withdrawal in Maintaining Opioid Addiction among Adults with Untreated Opioid Use Disorder: A Survey of Syringe Exchange Program Participants.成人未治疗阿片类药物使用障碍中停药对维持阿片类药物成瘾的感知作用:对注射器交换计划参与者的调查。
Subst Use Misuse. 2024;59(2):312-315. doi: 10.1080/10826084.2023.2269571. Epub 2023 Dec 28.
7
Opioid withdrawal symptoms, a consequence of chronic opioid use and opioid use disorder: Current understanding and approaches to management.阿片类药物戒断症状是慢性阿片类药物使用和阿片类药物使用障碍的后果:目前的认识和管理方法。
J Clin Pharm Ther. 2020 Oct;45(5):892-903. doi: 10.1111/jcpt.13114. Epub 2020 Jan 27.
8
Efficacy of Tramadol Extended-Release for Opioid Withdrawal: A Randomized Clinical Trial.曲马多缓释片用于阿片类药物戒断的疗效:一项随机临床试验。
JAMA Psychiatry. 2017 Sep 1;74(9):885-893. doi: 10.1001/jamapsychiatry.2017.1838.
9
The impact of depression on opioid withdrawal symptoms among smokers with opioid use disorder receiving medication-assisted opioid detoxification.抑郁症对接受药物辅助阿片类药物脱毒治疗的阿片类药物使用障碍吸烟者阿片类药物戒断症状的影响。
Exp Clin Psychopharmacol. 2023 Apr;31(2):370-377. doi: 10.1037/pha0000599. Epub 2022 Sep 8.
10
Effects of extended-release naltrexone on the brain response to drug-related stimuli in patients with opioid use disorder.美沙酮使用障碍患者中,纳曲酮长效制剂对药物相关刺激的大脑反应的影响。
J Psychiatry Neurosci. 2018 Jul;43(4):254-261. doi: 10.1503/jpn.170036.

引用本文的文献

1
Transcutaneous Cervical Vagus Nerve Stimulation Modulates Prefrontal Cortex Activity During Opioid Withdrawal in Individuals With Opioid Use Disorder.经皮颈迷走神经刺激调节阿片类物质使用障碍患者阿片类物质戒断期间的前额叶皮质活动。
Neuromodulation. 2025 Jun 23. doi: 10.1016/j.neurom.2025.04.012.
2
Are Treatment Services Ready for the Use of Big Data Analytics and AI in Managing Opioid Use Disorder?治疗服务机构是否准备好利用大数据分析和人工智能来管理阿片类药物使用障碍?
J Med Internet Res. 2025 Apr 28;27:e58723. doi: 10.2196/58723.
3
Acute and long-term effects of COVID-19 on brain and mental health: A narrative review.

本文引用的文献

1
Transcutaneous cervical vagus nerve stimulation reduces behavioral and physiological manifestations of withdrawal in patients with opioid use disorder: A double-blind, randomized, sham-controlled pilot study.经皮颈部迷走神经刺激可减轻阿片类药物使用障碍患者戒断的行为和生理表现:一项双盲、随机、假刺激对照的初步研究。
Brain Stimul. 2022 Sep-Oct;15(5):1206-1214. doi: 10.1016/j.brs.2022.08.017. Epub 2022 Aug 27.
2
Maternal opioid use disorder: Placental transcriptome analysis for neonatal opioid withdrawal syndrome.母亲阿片类药物使用障碍:新生儿阿片类药物戒断综合征的胎盘转录组分析
Genomics. 2021 Nov;113(6):3610-3617. doi: 10.1016/j.ygeno.2021.08.001. Epub 2021 Aug 3.
3
新型冠状病毒肺炎对大脑和心理健康的急性及长期影响:一项叙述性综述
Brain Behav Immun. 2025 Jan;123:928-945. doi: 10.1016/j.bbi.2024.11.007. Epub 2024 Nov 3.
4
Leveraging Trauma Informed Care for Digital Health Intervention Development in Opioid Use Disorder.利用创伤知情护理促进阿片类药物使用障碍数字健康干预的发展。
J Med Toxicol. 2025 Jan;21(1):60-68. doi: 10.1007/s13181-024-01040-x. Epub 2024 Oct 24.
5
Noninvasive Vagal Nerve Stimulation for Opioid Use Disorder.用于阿片类物质使用障碍的非侵入性迷走神经刺激
Ann Depress Anxiety. 2023;10(1). Epub 2023 Aug 2.
6
Digital Biomarker Applications Across the Spectrum of Opioid Use Disorder.数字生物标志物在阿片类物质使用障碍全谱中的应用
Cogent Ment Health. 2023;2(1). doi: 10.1080/28324765.2023.2240375. Epub 2023 Aug 1.
Placental DNA methylation profiles in opioid-exposed pregnancies and associations with the neonatal opioid withdrawal syndrome.
阿片类药物暴露妊娠中的胎盘DNA甲基化谱及其与新生儿阿片类药物戒断综合征的关联。
Genomics. 2021 May;113(3):1127-1135. doi: 10.1016/j.ygeno.2021.03.006. Epub 2021 Mar 9.
4
Identifying Opioid Withdrawal Using Wearable Biosensors.使用可穿戴生物传感器识别阿片类药物戒断症状。
Proc Annu Hawaii Int Conf Syst Sci. 2021 Jan;54:3583-3592.
5
Automated quantification of opioid withdrawal in neonatal rat pups using Ethovision® XT software.使用 Ethovision® XT 软件自动量化新生大鼠的阿片类戒断。
Neurotoxicol Teratol. 2021 Mar-Apr;84:106959. doi: 10.1016/j.ntt.2021.106959. Epub 2021 Jan 30.
6
Heart Rate Variability and Accelerometry as Classification Tools for Monitoring Perceived Stress Levels-A Pilot Study on Firefighters.心率变异性和加速度计作为监测消防员感知压力水平的分类工具——一项初步研究。
Sensors (Basel). 2020 May 16;20(10):2834. doi: 10.3390/s20102834.
7
Automatic Detection of Opioid Intake Using Wearable Biosensor.使用可穿戴生物传感器自动检测阿片类药物摄入量
Int Conf Comput Netw Commun. 2018 Mar;2018:784-788. doi: 10.1109/ICCNC.2018.8390334. Epub 2018 Jun 21.
8
Sleep reductions associated with illicit opioid use and clinic-hour changes during opioid agonist treatment for opioid dependence: Measurement by electronic diary and actigraphy.电子日记和活动记录仪测量的非法阿片类药物使用和阿片类激动剂治疗期间诊所时间变化与睡眠减少的关系:阿片类药物依赖的治疗。
J Subst Abuse Treat. 2019 Nov;106:43-57. doi: 10.1016/j.jsat.2019.08.011. Epub 2019 Aug 14.
9
Assessment of Ultra-Short Heart Variability Indices Derived by Smartphone Accelerometers for Stress Detection.使用智能手机加速度计评估超短时间心率变异性指标用于应激检测。
Sensors (Basel). 2019 Aug 28;19(17):3729. doi: 10.3390/s19173729.
10
Relationship between jerky and sinusoidal oscillations in cervical dystonia.颈部肌张力障碍中颠簸和正弦摆动之间的关系。
Parkinsonism Relat Disord. 2019 Sep;66:130-137. doi: 10.1016/j.parkreldis.2019.07.024. Epub 2019 Jul 20.